文献速递中医内科中药与中成药合理使用

药用植物及其活性代谢物靶向自噬通路治疗心力衰竭的研究进展

Research progress on targeting autophagy pathways with medicinal plants and their active metabolites for the treatment of heart failure.
PubMed 文献 · Front Pharmacol · 2026-09-04

该综述基于PubMed、CNKI、Web of Science和万方数据库及传统医学典籍,批判性审视药用植物通过调控自噬治疗心力衰竭的民族药理学证据。文中指出药用植物具有多靶点调控优势,但现有证据多来自基础或观察性研究,缺乏严格设计的随机对照试验验证,临床价值尚未确认。

要点

  • 药用植物通过调控自噬、抑制炎症和减轻氧化应激发挥潜在抗心衰作用。
  • 现有证据多属相关性观察,缺乏直接机制验证和严格随机对照试验。
  • 天然药物存在剂量依赖性毒性,不可默认比合成药物更安全。

核心结论

  • 药用植物在多靶点调控和安全性方面具有优势,但须谨慎解读,不应过度泛化「显著临床疗效」的主张。
  • 天然植物治疗心衰的临床价值尚未确认,亟需严格方法学和大规模临床试验验证。

研究设计与样本

  • 综述检索了PubMed、中国知网(CNKI)、Web of Science和万方数据库,并参考传统医学典籍。

主要发现

  • 药用植物及其活性代谢物可通过调控自噬、抑制炎症和减少氧化应激发挥潜在心衰治疗作用。
  • 现有数据主要来自基础研究或观察性研究,而非严格设计的随机对照试验。
  • 中药复方呈现「多代谢物、多靶点、多通路」作用,无法用单一通路解释。

临床怎么用

  • 从传统应用向循证治疗转化面临标准化、质量控制和剂量优化方面的挑战。
  • 需开展严格方法学的大规模临床试验确认药用植物治疗心衰的患者获益。

局限性

  • 广谱活性引发对靶点特异性和脱靶效应的担忧。
  • 当前证据多依赖相关性观察而非直接机制验证。
  • 天然产物存在剂量依赖性毒性且缺乏长期临床数据,不能默认比合成药物更安全。
  • 还原论式分离活性代谢物可能忽略全草药制剂的协同作用。
  • 多自噬相关通路调控的理论优势尚缺乏严格随机对照试验数据支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the therapeutic promise of natural plants in preclinical models, their clinical value for heart failure (HF) remains unconfirmed and requires rigorous validation through well-designed trials. HF severely impairs quality of life, and natural plant therapies-known for their multi-metabolites and multi-target effects-have been explored as potential treatments via modulation of autophagy, inhibition of inflammation, and reduction of oxidative stress. However, several critical issues remain unresolved: the broad-spectrum activity raises concerns about target specificity and off-target effects. Current evidence largely relies on correlative observations rather than direct mechanistic validation. The assumption that natural products are inherently safer than synthetic drugs is flawed due to dose-dependent toxicity and the absence of long-term clinical data. And the reductionist isolation of active metabolites may overlook the synergistic actions of whole herbal preparations. Moreover, while modulation of multiple autophagy-related pathways is theoretically superior, existing data stem primarily from basic or observational studies rather than from rigorously designed randomized controlled trials. Chinese herbal formulas exhibit "multi-metabolite, multi-target, multi-pathway" actions that cannot be explained by a single pathway, and the transition from traditional use to evidence-based therapy faces challenges in standardization, quality control, and dose optimization. This review critically examines the ethnopharmacological use of natural plants in HF through autophagy regulation, drawing on traditional medicine classics and databases including PubMed, China National Knowledge Infrastructure (CNKI), Web of Science, and Wanfang. Our key findings indicate that medicinal plants offer advantages in multi-target regulation and safety, but these potential benefits must be interpreted with caution. Claims of "significant clinical efficacy" should not be overgeneralized. Thus, rigorous methodologies and large-scale clinical trials are urgently needed to confirm whether natural plant therapies can truly translate into tangible benefits for HF patients.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Dong Y, Wang Y, Kou X, et al. Research progress on targeting autophagy pathways with medicinal plants and their active metabolites for the treatment of heart failure. Front Pharmacol. 2026. PMID: 42761791. doi:10.3389/fphar.2026.1908479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。